• Je něco špatně v tomto záznamu ?

Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer

E. Laukhtina, P. Gontero, M. Babjuk, M. Moschini, JY. Teoh, M. Rouprêt, QD. Trinh, P. Chlosta, P. Nyirády, M. Abufaraj, F. Soria, J. Klemm, K. Bekku, A. Matsukawa, SF. Shariat

. 2024 ; 134 (4) : 644-651. [pub] 20240416

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018824

OBJECTIVE: To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), as due to the poorly-defined and overlapping diagnostic criteria optimal decision-making remains challenging in these patients. PATIENTS AND METHODS: In this multicentre study, patients treated with transurethral resection of bladder tumour for Ta disease were retrospectively analysed. All patients with low- or high-risk NMIBC were excluded from the analysis. Associations between adjuvant therapy administration with recurrence-free survival (RFS) and progression-free survival (PFS) rates were assessed in Cox regression models. RESULTS: A total of 2206 patients with intermediate-risk NMIBC were included in the analysis. Among them, 1427 patients underwent adjuvant therapy, such as bacille Calmette-Guérin (n = 168), or chemotherapeutic agents, such as mitomycin C or epirubicin (n = 1259), in different regimens up to 1 year. The median (interquartile range) follow-up was 73.3 (38.4-106.9) months. The RFS at 1 and 5 years in patients treated with adjuvant therapy and those without were 72.6% vs 69.5% and 50.8% vs 41.3%, respectively. Adjuvant therapy was associated with better RFS (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.70-0.89, P < 0.001), but not with PFS (P = 0.09). In the subgroup of patients aged ≤70 years with primary, single Ta Grade 2 <3 cm tumours (n = 328), adjuvant therapy was not associated with RFS (HR 0.71, 95% CI 0.50-1.02, P = 0.06). While in the subgroup of patients with at least one risk factor including patient age >70 years, tumour multiplicity, recurrent tumour and tumour size ≥3 cm (n = 1878), adjuvant intravesical therapy was associated with improved RFS (HR 0.78, 95% CI 0.68-0.88, P < 0.001). CONCLUSION: In our study, patients with intermediate-risk NMIBC benefit from adjuvant intravesical therapy in terms of RFS. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018824
003      
CZ-PrNML
005      
20241024111328.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.16371 $2 doi
035    __
$a (PubMed)38627025
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000289530272
245    10
$a Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer / $c E. Laukhtina, P. Gontero, M. Babjuk, M. Moschini, JY. Teoh, M. Rouprêt, QD. Trinh, P. Chlosta, P. Nyirády, M. Abufaraj, F. Soria, J. Klemm, K. Bekku, A. Matsukawa, SF. Shariat
520    9_
$a OBJECTIVE: To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), as due to the poorly-defined and overlapping diagnostic criteria optimal decision-making remains challenging in these patients. PATIENTS AND METHODS: In this multicentre study, patients treated with transurethral resection of bladder tumour for Ta disease were retrospectively analysed. All patients with low- or high-risk NMIBC were excluded from the analysis. Associations between adjuvant therapy administration with recurrence-free survival (RFS) and progression-free survival (PFS) rates were assessed in Cox regression models. RESULTS: A total of 2206 patients with intermediate-risk NMIBC were included in the analysis. Among them, 1427 patients underwent adjuvant therapy, such as bacille Calmette-Guérin (n = 168), or chemotherapeutic agents, such as mitomycin C or epirubicin (n = 1259), in different regimens up to 1 year. The median (interquartile range) follow-up was 73.3 (38.4-106.9) months. The RFS at 1 and 5 years in patients treated with adjuvant therapy and those without were 72.6% vs 69.5% and 50.8% vs 41.3%, respectively. Adjuvant therapy was associated with better RFS (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.70-0.89, P < 0.001), but not with PFS (P = 0.09). In the subgroup of patients aged ≤70 years with primary, single Ta Grade 2 <3 cm tumours (n = 328), adjuvant therapy was not associated with RFS (HR 0.71, 95% CI 0.50-1.02, P = 0.06). While in the subgroup of patients with at least one risk factor including patient age >70 years, tumour multiplicity, recurrent tumour and tumour size ≥3 cm (n = 1878), adjuvant intravesical therapy was associated with improved RFS (HR 0.78, 95% CI 0.68-0.88, P < 0.001). CONCLUSION: In our study, patients with intermediate-risk NMIBC benefit from adjuvant intravesical therapy in terms of RFS. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x patologie $x terapie $x farmakoterapie $x mortalita $7 D001749
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a aplikace intravezikální $7 D000283
650    _2
$a lidé středního věku $7 D008875
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a BCG vakcína $x terapeutické užití $x aplikace a dávkování $7 D001500
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a mitomycin $x aplikace a dávkování $x terapeutické užití $7 D016685
650    _2
$a cystektomie $x metody $7 D015653
650    _2
$a epirubicin $x aplikace a dávkování $7 D015251
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a nádory močového měchýře neinvadující svalovinu $7 D000093284
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Gontero, Paolo $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
700    1_
$a Babjuk, Marko $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Moschini, Marco $u Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0000000230842458
700    1_
$a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000293612342
700    1_
$a Rouprêt, Morgan $u Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France
700    1_
$a Trinh, Quoc-Dien $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000338579276
700    1_
$a Chlosta, Piotr $u Department of Urology, Jagiellonian University, Cracow, Poland
700    1_
$a Nyirády, Péter $u Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Abufaraj, Mohammad $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $1 https://orcid.org/0000000266036319
700    1_
$a Soria, Francesco $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy $1 https://orcid.org/0000000184438453
700    1_
$a Klemm, Jakob $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000300021592
700    1_
$a Matsukawa, Akihiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/000000023324762X
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, Semmelweis University, Budapest, Hungary $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 134, č. 4 (2024), s. 644-651
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38627025 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111321 $b ABA008
999    __
$a ok $b bmc $g 2201592 $s 1230797
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 134 $c 4 $d 644-651 $e 20240416 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace